Repository logo
 
Publication

Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II

dc.contributor.authorMatos, Liliana
dc.contributor.authorGonçalves, Vânia
dc.contributor.authorPinto, Eugénia
dc.contributor.authorLaranjeira, Francisco
dc.contributor.authorPrata, Maria João
dc.contributor.authorJordan, Peter
dc.contributor.authorDesviat, Lourdes R.
dc.contributor.authorPerez, Belén
dc.contributor.authorAlves, Sandra
dc.date.accessioned2016-02-18T17:17:06Z
dc.date.available2019-01-01T01:30:10Z
dc.date.issued2015-12
dc.description.abstractMucopolysaccharidosis II is a lysosomal storage disorder caused by mutations in the IDS gene, including exonic alterations associated with aberrant splicing. In the present work, cell-based splicing assays were performed to study the effects of two splicing mutations in exon 3 of IDS, i.e., c.241C>T and c.257C>T, whose presence activates a cryptic splice site in exon 3 and one in exon 8, i.e., c.1122C>T that despite being a synonymous mutation is responsible for the creation of a new splice site in exon 8 leading to a transcript shorter than usual. Mutant minigene analysis and overexpression assays revealed that SRSF2 and hnRNP E1 might be involved in the use and repression of the constitutive 3' splice site of exon 3 respectively. For the c.1122C>T the use of antisense therapy to correct the splicing defect was explored, but transfection of patient fibroblasts with antisense morpholino oligonucleotides (n=3) and a locked nucleic acid failed to abolish the abnormal transcript; indeed, it resulted in the appearance of yet another aberrant splicing product. Interestingly, the oligonucleotides transfection in control fibroblasts led to the appearance of the aberrant transcript observed in patients' cells after treatment, which shows that the oligonucleotides are masking an important cis-acting element for 5' splice site regulation of exon 8. These results highlight the importance of functional studies for understanding the pathogenic consequences of mis-splicing and highlight the difficulty in developing antisense therapies involving gene regions under complex splicing regulation.pt_PT
dc.description.sponsorshipLM was supported by a grant (SFRH/BD/64592/2009) from the Fundação para a Ciência e Tecnologia IP (FCT)/POPH/FSE, Portugal.pt_PT
dc.identifier.citationBiochim Biophys Acta. 2015 Dec;1852(12):2712-21. doi: 10.1016/j.bbadis.2015.09.011. Epub 2015 Sep 25pt_PT
dc.identifier.doi10.1016/j.bbadis.2015.09.011pt_PT
dc.identifier.issn0006-3002
dc.identifier.urihttp://hdl.handle.net/10400.18/3429
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevierpt_PT
dc.relation.publisherversionhttp://www.sciencedirect.com/science/article/pii/S0925443915002835pt_PT
dc.subjectDoenças Genéticaspt_PT
dc.subjectLysosomal Storage Disorderspt_PT
dc.subjectSplicing Regulationpt_PT
dc.subjectMutationpt_PT
dc.subjectAntisense Therapypt_PT
dc.subjectIDS genept_PT
dc.titleFunctional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS IIpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage2721pt_PT
oaire.citation.startPage2712pt_PT
oaire.citation.titleBBA - Biochimica et Biophysica Acta - Molecular Basis of Diseasept_PT
oaire.citation.volume1852(12)pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
IDS splicing mutation_Liliana BBA 2015.pdf
Size:
823.22 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: